| アブストラクト | BACKGROUND: The objective of this study will be to synthesize the epidemiological evidence and evaluate the validity of the associations between central nervous system disorders and the risk of developing or dying from cancer. METHODS/DESIGN: We will perform an umbrella review of systematic reviews and conduct updated meta-analyses of observational studies (cohort and case-control) investigating the association between central nervous system disorders and the risk of developing or dying from any cancer or specific types of cancer. Searches involving PubMed/MEDLINE, EMBASE, SCOPUS and Web of Science will be used to identify systematic reviews and meta-analyses of observational studies. In addition, online databases will be checked for observational studies published outside the time frames of previous reviews. Eligible central nervous system disorders will be Alzheimer's disease, anorexia nervosa, amyotrophic lateral sclerosis, autism spectrum disorders, bipolar disorder, depression, Down's syndrome, epilepsy, Huntington's disease, multiple sclerosis, Parkinson's disease and schizophrenia. The primary outcomes will be cancer incidence and cancer mortality in association with a central nervous system disorder. Secondary outcome measures will be site-specific cancer incidence and mortality, respectively. Two reviewers will independently screen references identified by the literature search, as well as potentially relevant full-text articles. Data will be abstracted, and study quality/risk of bias will be appraised by two reviewers independently. Conflicts at all levels of screening and abstraction will be resolved through discussion. Random-effects meta-analyses of primary observational studies will be conducted where appropriate. Parameters for exploring statistical heterogeneity are pre-specified. The World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR) criteria and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach will be used for determining the quality of evidence for cancer outcomes. DISCUSSION: Our study will establish the extent of the epidemiological evidence underlying the associations between central nervous system disorders and cancer and will provide a rigorous and updated synthesis of a range of important site-specific cancer outcomes. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42016052762. |
|---|
| 投稿者 | Catala-Lopez, Ferran; Hutton, Brian; Driver, Jane A; Page, Matthew J; Ridao, Manuel; Valderas, Jose M; Alonso-Arroyo, Adolfo; Fores-Martos, Jaume; Martinez, Salvador; Genova-Maleras, Ricard; Macias-Saint-Gerons, Diego; Crespo-Facorro, Benedicto; Vieta, Eduard; Valencia, Alfonso; Tabares-Seisdedos, Rafael |
|---|
| 組織名 | Department of Medicine, University of Valencia/INCLIVA Health Research Institute;and CIBERSAM, Valencia, Spain. ferran_catala@hotmail.com.;Fundacion Instituto de Investigacion en Servicios de Salud, Valencia, Spain.;ferran_catala@hotmail.com.;Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa,;Ontario, Canada. ferran_catala@hotmail.com.;Ontario, Canada.;School of Epidemiology, Public Health and Preventive Medicine, University of;Ottawa, Ottawa, Ontario, Canada.;Geriatric Research Education and Clinical Center, VA Boston Healthcare System,;Boston, MA, USA.;Division of Aging, Department of Medicine, Brigham and Women's Hospital, Harvard;Medical School, Boston, MA, USA.;School of Public Health and Preventive Medicine, Monash University, Melbourne,;Victoria, Australia.;School of Social and Community Medicine, University of Bristol, Bristol, UK.;Instituto Aragones de Ciencias de la Salud, Red de Investigacion en Servicios de;Salud en Enfermedades Cronicas (REDISSEC), Zaragoza, Spain.;Fundacion para el Fomento de la Investigacion Sanitaria y Biomedica de la;Comunitat Valenciana (FISABIO-Salud Publica), Valencia, Spain.;Health Services and Policy Research Group, Exeter Collaboration for Academic;Primary Care, University of Exeter Medical School, University of Exeter, Exeter,;UK.;Department of History of Science and Documentation, University of Valencia,;Valencia, Spain.;Unidad de Informacion e Investigacion Social y Sanitaria-UISYS, University of;Valencia-Spanish National Research Council (CSIC), Valencia, Spain.;and CIBERSAM, Valencia, Spain.;Instituto de Neurociencias de Alicante, Universidad Miguel Hernandez-Spanish;National Research Council (UMH-CSIC), San Juan de Alicante, Spain.;Directorate General for Public Health, Regional Health Council, Madrid, Spain.;Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Medicines and;Healthcare Products Agency (AEMPS), Madrid, Spain.;Department of Health Systems and Services, Unit of Medicines and Health;Technologies, Pan American Health Organization (PAHO), Washington, DC, USA.;Department of Psychiatry, Hospital Marques de Valdecilla, University of;Cantabria/IDIVAL and CIBERSAM, Santander, Spain.;Hospital Clinic, Universitat de Barcelona, Institut d'Investigacions Biomediques;August Pi i Sunyer (IDIBAPS) and CIBERSAM, Barcelona, Spain.;Structural Biology and Biocumputing Programme, Spanish National Cancer Research;Centre (CNIO), Madrid, Spain.;Life Sciences Department, Barcelona Supercomputing Center, Barcelona, Spain.;and CIBERSAM, Valencia, Spain. rafael.tabares@uv.es. |
|---|
